Wanbury Limited — Updates, 15-11-2024: Press Release

Q2 FY25 Revenue from operations for Wanbury Ltd. reached Rs. 161.2 crore, a growth of 11.6% year-on-year, supported by increased sales volumes of key products like Metformin and Sertraline, alongside growth in the Branded Formulation segment. EBITDA improved to Rs. 21.6 crore, rising 19.6% y-o-y, with margins at 13.4%. The company reported a PAT of Rs. 8.0 crore, reflecting an 8.9% increase compared to the previous year. Notably, the Patalganga manufacturing site secured two safety awards and received a positive USFDA inspection report, indicating no regulatory concerns. Looking ahead, Wanbury is expanding its API product range with plans to launch three new APIs and expects to enhance productivity post-upgrades at the Tanuku facility, set for completion in December 2024. The capability to export Dextromethorphan to Europe is another positive development, paving the way for market expansion. The company's strategic focus on cost improvement through process engineering aims to support margin enhancements, signaling a positive outlook for growth.